Literature DB >> 25003291

Age-related guideline adherence and outcome in low rectal cancer.

Anandi H W Schiphorst1, Norbert M Verweij, Apollo Pronk, Marije E Hamaker.   

Abstract

BACKGROUND: Care for elderly patients with low rectal cancer can pose dilemmas, because radical total mesorectal excision surgery comes with high morbidity and mortality rates.
OBJECTIVE: The purpose of this study was to analyze the treatment of patients with low rectal cancer, comparing treatment choices, guideline adherence, and outcomes for elderly patients (≥75 years) with younger patients (<75 years).
DESIGN: Patient data were retrieved from the hospital pathology database and from the hospital prospective colorectal surgery database for surgically treated patients. Records were reviewed for nonadherence to treatment guidelines. Delivered treatment modalities for patients with stage I to III rectal cancer were compared with treatment advised by national guidelines, and reasons stated by the treating physician for nonadherence to guidelines were subsequently collected. SETTINGS: This study was performed at a high-volume teaching hospital. PATIENTS: Patients included were those with newly diagnosed rectal cancer (≤10 cm from the anal verge). MAIN OUTCOME MEASURES: Treatment decisions, guideline adherence, and outcome of surgical treatment were the main outcome parameters.
RESULTS: Of 218 included patients, 75 (34%) were aged ≥75 years. Guideline adherence for all of the treatment modalities in stage I to III rectal cancer was significantly lower in elderly patients (62% versus 87% for aged <75 years; p < 0.001), and age was the primary reason mentioned for withholding treatment. Palliative anticancer treatment for stage IV disease was also initiated significantly less frequently in elderly patients (60% versus 97%; p = 0.002). Overall rates of treatment complications were similar for both patient groups (p = 0.71), but the impact of complications on survival was much greater for elderly patients (p = 0.002). LIMITATIONS: Data on outcome of other treatment modalities, such as chemotherapy and radiotherapy, are lacking.
CONCLUSIONS: Guideline adherence for all of the treatment modalities in stage I to III rectal cancer declines significantly with increasing age. Future research should focus on strategies of treatment tailored to patient health status rather than chronological age.

Entities:  

Mesh:

Year:  2014        PMID: 25003291     DOI: 10.1097/DCR.0000000000000145

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  8 in total

Review 1.  [Surgical treatment of colorectal carcinoma in the elderly].

Authors:  J Schuld; M Glanemann
Journal:  Chirurg       Date:  2017-02       Impact factor: 0.955

2.  Guideline adherence and implementation of tumor board therapy recommendations for patients with gastrointestinal cancer.

Authors:  Alina Krause; Gertraud Stocker; Ines Gockel; Daniel Seehofer; Albrecht Hoffmeister; Hendrik Bläker; Timm Denecke; Regine Kluge; Florian Lordick; Maren Knödler
Journal:  J Cancer Res Clin Oncol       Date:  2022-04-08       Impact factor: 4.553

3.  Impact of Age on Multimodality Treatment and Survival in Locally Advanced Rectal Cancer Patients.

Authors:  Lindsey C F De Nes; Thea C Heil; Rob H A Verhoeven; Valery E P P Lemmens; Harm J Rutten; Johannes H W De Wilt; Pauline A J Vissers
Journal:  Cancers (Basel)       Date:  2022-05-31       Impact factor: 6.575

Review 4.  A Multidisciplinary Approach for the Personalised Non-Operative Management of Elderly and Frail Rectal Cancer Patients Unable to Undergo TME Surgery.

Authors:  Stijn H J Ketelaers; Anne Jacobs; An-Sofie E Verrijssen; Jeltsje S Cnossen; Irene E G van Hellemond; Geert-Jan M Creemers; Ramon-Michel Schreuder; Harm J Scholten; Jip L Tolenaar; Johanne G Bloemen; Harm J T Rutten; Jacobus W A Burger
Journal:  Cancers (Basel)       Date:  2022-05-11       Impact factor: 6.575

5.  The C-reactive protein to albumin ratio predicts postoperative complications in oldest-old patients with colorectal cancer.

Authors:  Shintaro Hashimoto; Tetsuro Tominaga; Takashi Nonaka; Kiyoaki Hamada; Masato Araki; Hiroaki Takeshita; Hidetoshi Fukuoka; Hideo Wada; Kazuo To; Hideaki Komatsu; Kenji Tanaka; Terumitsu Sawai; Takeshi Nagayasu
Journal:  Int J Colorectal Dis       Date:  2020-01-02       Impact factor: 2.571

6.  The other side of screening: predictors of treatment and follow-up for anal precancers in a large health system.

Authors:  Richard Silvera; Tyler Martinson; Michael M Gaisa; Yuxin Liu; Ashish A Deshmukh; Keith Sigel
Journal:  AIDS       Date:  2021-11-01       Impact factor: 4.177

7.  Impact of age on efficacy of postoperative oxaliplatin-based chemotherapy in patients with rectal cancer after neoadjuvant chemoradiotherapy.

Authors:  Xuan-Zhang Huang; Peng Gao; Yong-Xi Song; Jing-Xu Sun; Xiao-Wan Chen; Jun-Hua Zhao; Bin Ma; Jun Wang; Zhen-Ning Wang
Journal:  Oncotarget       Date:  2016-04-12

8.  KRAS biomarker testing disparities in colorectal cancer patients in New Mexico.

Authors:  Alissa Greenbaum; Charles Wiggins; Angela Lw Meisner; Manuel Rojo; Anita Y Kinney; Ashwani Rajput
Journal:  Heliyon       Date:  2017-11-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.